Alnylam Pharmaceuticals, Inc.
LSE: 0HD2.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Yvonne L. Greenstreet
- Employees
- 2,230
- Headquarters
- Cambridge, United States
- IPO year
- 2018
- Market cap
- $39.5B
- Website
- https://www.alnylam.com
Loading 0HD2…
Loading profile data…Frequently asked questions about 0HD2
What does Alnylam Pharmaceuticals, Inc. (0HD2.L) do?
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
Where does 0HD2.L trade?
Alnylam Pharmaceuticals, Inc. (0HD2.L) trades on the London Stock Exchange.
What sector is 0HD2.L in?
Alnylam Pharmaceuticals, Inc. (0HD2.L) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Alnylam Pharmaceuticals, Inc.?
Yvonne L. Greenstreet is the chief executive officer of Alnylam Pharmaceuticals, Inc. (0HD2.L).
Where is Alnylam Pharmaceuticals, Inc. headquartered?
Alnylam Pharmaceuticals, Inc. is headquartered in United States.
Does 0HD2.L pay a dividend?
Alnylam Pharmaceuticals, Inc. (0HD2.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0HD2.L go public?
Alnylam Pharmaceuticals, Inc. (0HD2.L) completed its initial public offering in 2018.